Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.84 |
| ▸ | SHBG | P04278 | 6/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.84 |
| ▸ | SERPINA6 | P08185 | 5/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.84 |
| ▸ | LMNA | P02545 | 4/20 | 0.84 |
| ▸ | TSHR | P16473 | 3/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.84 |
| ▸ | BLM | P54132 | 2/20 | 0.84 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.84 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.78 |
| ▸ | PGR | P06401 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24358662 | 1.00 | HSD17B10 (0.84) | HSD17B10SHBGSMN1; SMN2CYP2C19SERPINA6 | |
| Cortodoxone SCHEMBL42590 | 0.91 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2CYP2C19SERPINA6 | |
| SCHEMBL12239754 | 0.91 | HSD17B10 (0.84) | HSD17B10SHBGSMN1; SMN2CYP2C19SERPINA6 | |
| Cortodoxone SCHEMBL13768127 | 0.91 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2CYP2C19SERPINA6 | |
| Cortodoxone SCHEMBL24900239 | 0.91 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2CYP2C19SERPINA6 | |
| SCHEMBL6019058 | 0.91 | HSD17B10 (0.84) | HSD17B10SHBGSMN1; SMN2CYP2C19SERPINA6 | |
| Cortodoxone SCHEMBL17906542 | 0.91 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2CYP2C19SERPINA6 | |
| Cortodoxone SCHEMBL13352414 | 0.91 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2CYP2C19SERPINA6 | |
| Cortodoxone SCHEMBL14360590 | 0.91 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2CYP2C19SERPINA6 | |
| Cortodoxone SCHEMBL1592718 | 0.91 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2CYP2C19SERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5332847-A | Process for the preparation of 21-bromo-4-pregnene-3,20-dione derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-07-26 | — | — | US | claimed |
| CN-122042848-A | Method for separating and measuring key starting materials and related compounds of clavulanone by HPLC (high Performance liquid chromatography) | 福建大谱生物医药有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20240018181-A1 | PROCESS FOR THE PRODUCTION OF 21-(ACETYLOXY)-17-(PROPIONYLOXY)-PREGN-4-ENE-3,20-DIONE | INDUSTRIALE CHIMICA S.R.L. (IT) | 2024-01-18 | — | — | US | disclosed |
| US-5506354-A | ANTIULCER, ANTITURMOR, ANTIARTHRITIC, ANTIATHEROSCLEROSIS, ANTIALLERGIC, ANTIASTHMA AGENTS | THE UPJOHN COMPANY (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0238545-B1 | C20 THROUGH C26 AMINO STEROIDS | UPJOHN CO (US) | 1995-11-15 | — | — | EP | disclosed |
| US-RE35053-E | Intermediates for amino substituted steroids | THE UPJOHN COMPANY (US) | 1995-10-10 | — | — | US | disclosed |
| EP-0263213-B1 | C20 Through C26 amino steroids | UPJOHN CO (US) | 1995-09-06 | — | — | EP | disclosed |
| EP-0431151-B1 | METHOD FOR PREPARING 21-BROM-4-PREGNEN-3,20-DIONE DERIVATIVES | SCHERING AG (DE) | 1995-03-15 | — | — | EP | disclosed |
| US-5382661-A | Useful in treating spinal trauma, head injury, subarachnoid hemorrhage | THE UPJOHN COMPANY (US) | 1995-01-17 | — | — | US | disclosed |
| US-5380839-A | Antitumor agents, antisecretory agents, enzyme inhibitors or antiasthmatics | THE UPJOHN COMPANY (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0153001-B1 | STEROIDS HAVING AN ENAMIDE OR ENIMIDE GROUP AND THEIR PREPARATION | THE UPJOHN COMPANY (US) | 1992-03-11 | — | — | EP | disclosed |
| US-4831131-A | 11β,17α-Dihydroxy-17β-cyano-androstanes | THE UPJOHN COMPANY (US) | 1989-05-16 | — | — | US | disclosed |
| EP-0263213-A1 | C20 Through C26 amino steroids | THE UPJOHN COMPANY (US) | 1988-04-13 | — | — | EP | disclosed |
| EP-0238545-A1 | C 20? THROUGH C 26? AMINO STEROIDS. | UPJOHN CO (US) | 1987-09-30 | — | — | EP | disclosed |
| WO-1987001706-A2 | C20 THROUGH C26 AMINO STEROIDS | THE UPJOHN COMPANY (US) | 1987-03-26 | — | — | WO | disclosed |
| US-4585590-A | Cyanohydrin process | THE UPJOHN COMPANY (US) | 1986-04-29 | — | — | US | disclosed |
| US-4548748-A | Cyanohydrin process | THE UPJOHN COMPANY (US) | 1985-10-22 | — | — | US | disclosed |
| EP-0153001-A2 | Steroids having an enamide or enimide group and their preparation | THE UPJOHN COMPANY (US) | 1985-08-28 | — | — | EP | disclosed |
| US-4500461-A | Cyanohydrin process | THE UPJOHN COMPANY (US) | 1985-02-19 | — | — | US | disclosed |
| US-4041055-A | SULFENYLATION, MICHAEL ADDITION, REACTION WITH THIOPHILE, HYDROLYSIS | THE UPJOHN COMPANY (US) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018181-A1 | PROCESS FOR THE PRODUCTION OF 21-(ACETYLOXY)-17-(PROPIONYLOXY)-PREGN-4-ENE-3,20-DIONE | CYP17A1, HSD17B11, HSD17B7 | HSD17B10 27/4885SHBG 177/4885SMN1; SMN2 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.